Literature DB >> 7307425

Plasma propranolol before, during, and after cardiopulmonary bypass.

J R Plachetka, N W Salomon, J G Copeland.   

Abstract

We evaluated changes in propranolol plasma levels before, during, and after cardiopulmonary bypass (CPB). Two groups of patients were studied, all of whom had been on long-term propranolol and had received their last oral dose 10 to 15 hr before surgery. Approximately 100 min before CPB began group 1 patients (n = 7) received 0.1 mg/kg propranolol intravenously while group II patients (n = 7) received a placebo. Before CPB the plasma propranolol levels fell in accordance with published descriptions for nonsurgical patients receiving oral and intravenous propranolol. Thereafter, the changes in the plasma levels were much the same in both groups. With the onset of CPB, the plasma levels decreased by approximately 50%. There was an insignificant fall in plasma levels during CPB, but the most interesting observation was made after : in each patient, the plasma levels obtained 5, 60, 120, and 240 min after CPB were higher than the last level during CPB. Mean plasma levels did not decline in either group during the 4-hr period. Although the reason for the sustained rise in the propranolol levels after CPB is not known, we suggest that it is due to the redistribution of propranolol from the lungs of the plasma coupled with reduction in hepatic elimination.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307425     DOI: 10.1038/clpt.1981.233

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Propranolol treatment in children with tetralogy of Fallot alters the response to isoprenaline after surgical repair.

Authors:  C Barazzone; C Jaccard; M Berner; P Dayer; J C Rouge; I Oberhansli; B Friedli
Journal:  Br Heart J       Date:  1988-08

2.  Alcuronium kinetics in patients undergoing cardiopulmonary bypass surgery.

Authors:  J S Walker; K F Brown; C A Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

3.  The effect of cardiopulmonary bypass on plasma protein binding of alfentanil.

Authors:  K Kumar; D P Crankshaw; D J Morgan; G H Beemer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Cardiopulmonary bypass and the pharmacokinetics of drugs. An update.

Authors:  W A Buylaert; L L Herregods; E P Mortier; M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

5.  Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass.

Authors:  W G Kramer; A Romagnoli
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition.

Authors:  K J Klamerus; K A Rodvold; N A Silverman; S Levitsky
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.